A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study

R. Daglas, S. M. Cotton, K. Allott, M. Yucel, C. A. Macneil, M. K. Hasty, B. Murphy, C. Pantelis, K. T. Hallam, L. P. Henry, P. Conus, A. Ratheesh, L. Kader, M. TH. Wong, P. D. McGorry, M. Berk

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Cognitive deficits have been reported during the early stages of bipolar disorder; however, the role of medication on such deficits remains unclear. The aim of this study was to compare the effects of lithium and quetiapine monotherapy on cognitive performance in people following first episode mania. Methods: The design was a single-blind, randomised controlled trial on a cohort of 61 participants following first episode mania. Participants received either lithium or quetiapine monotherapy as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive cognitive assessment battery conducted at baseline, month 3 and month 12 follow-up time-points. Results: There was a significant interaction between group and time in phonemic fluency at the 3-month and 12-month endpoints, reflecting greater improvements in performance in lithium-treated participants relative to quetiapine-treated participants. After controlling for multiple comparisons, there were no other significant interactions between group and time for other measures of cognition. Conclusion: Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder. Given that cognition is a major symptomatic domain of bipolar disorder and has substantive effects on general functioning, the ability to influence the trajectory of cognitive change is of considerable clinical importance.
Original languageEnglish
Pages (from-to)20-28
Number of pages9
JournalEuropean Psychiatry
Volume31
DOIs
Publication statusPublished - Jan 2016

Keywords

  • Mania
  • Bipolar disorder
  • Cognition
  • Lithium
  • Quetiapine
  • Early intervention

Cite this

Daglas, R. ; Cotton, S. M. ; Allott, K. ; Yucel, M. ; Macneil, C. A. ; Hasty, M. K. ; Murphy, B. ; Pantelis, C. ; Hallam, K. T. ; Henry, L. P. ; Conus, P. ; Ratheesh, A. ; Kader, L. ; Wong, M. TH. ; McGorry, P. D. ; Berk, M. / A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania : A 12-month follow-up study. In: European Psychiatry. 2016 ; Vol. 31. pp. 20-28.
@article{cd7d469a7da9439a857d811114a138fe,
title = "A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study",
abstract = "Background: Cognitive deficits have been reported during the early stages of bipolar disorder; however, the role of medication on such deficits remains unclear. The aim of this study was to compare the effects of lithium and quetiapine monotherapy on cognitive performance in people following first episode mania. Methods: The design was a single-blind, randomised controlled trial on a cohort of 61 participants following first episode mania. Participants received either lithium or quetiapine monotherapy as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive cognitive assessment battery conducted at baseline, month 3 and month 12 follow-up time-points. Results: There was a significant interaction between group and time in phonemic fluency at the 3-month and 12-month endpoints, reflecting greater improvements in performance in lithium-treated participants relative to quetiapine-treated participants. After controlling for multiple comparisons, there were no other significant interactions between group and time for other measures of cognition. Conclusion: Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder. Given that cognition is a major symptomatic domain of bipolar disorder and has substantive effects on general functioning, the ability to influence the trajectory of cognitive change is of considerable clinical importance.",
keywords = "Mania, Bipolar disorder, Cognition, Lithium, Quetiapine, Early intervention",
author = "R. Daglas and Cotton, {S. M.} and K. Allott and M. Yucel and Macneil, {C. A.} and Hasty, {M. K.} and B. Murphy and C. Pantelis and Hallam, {K. T.} and Henry, {L. P.} and P. Conus and A. Ratheesh and L. Kader and Wong, {M. TH.} and McGorry, {P. D.} and M. Berk",
year = "2016",
month = "1",
doi = "10.1016/j.eurpsy.2015.09.460",
language = "English",
volume = "31",
pages = "20--28",
journal = "European Psychiatry",
issn = "0924-9338",
publisher = "Elsevier",

}

A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania : A 12-month follow-up study. / Daglas, R.; Cotton, S. M.; Allott, K.; Yucel, M.; Macneil, C. A.; Hasty, M. K.; Murphy, B.; Pantelis, C.; Hallam, K. T.; Henry, L. P.; Conus, P.; Ratheesh, A.; Kader, L.; Wong, M. TH.; McGorry, P. D.; Berk, M.

In: European Psychiatry, Vol. 31, 01.2016, p. 20-28.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania

T2 - A 12-month follow-up study

AU - Daglas, R.

AU - Cotton, S. M.

AU - Allott, K.

AU - Yucel, M.

AU - Macneil, C. A.

AU - Hasty, M. K.

AU - Murphy, B.

AU - Pantelis, C.

AU - Hallam, K. T.

AU - Henry, L. P.

AU - Conus, P.

AU - Ratheesh, A.

AU - Kader, L.

AU - Wong, M. TH.

AU - McGorry, P. D.

AU - Berk, M.

PY - 2016/1

Y1 - 2016/1

N2 - Background: Cognitive deficits have been reported during the early stages of bipolar disorder; however, the role of medication on such deficits remains unclear. The aim of this study was to compare the effects of lithium and quetiapine monotherapy on cognitive performance in people following first episode mania. Methods: The design was a single-blind, randomised controlled trial on a cohort of 61 participants following first episode mania. Participants received either lithium or quetiapine monotherapy as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive cognitive assessment battery conducted at baseline, month 3 and month 12 follow-up time-points. Results: There was a significant interaction between group and time in phonemic fluency at the 3-month and 12-month endpoints, reflecting greater improvements in performance in lithium-treated participants relative to quetiapine-treated participants. After controlling for multiple comparisons, there were no other significant interactions between group and time for other measures of cognition. Conclusion: Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder. Given that cognition is a major symptomatic domain of bipolar disorder and has substantive effects on general functioning, the ability to influence the trajectory of cognitive change is of considerable clinical importance.

AB - Background: Cognitive deficits have been reported during the early stages of bipolar disorder; however, the role of medication on such deficits remains unclear. The aim of this study was to compare the effects of lithium and quetiapine monotherapy on cognitive performance in people following first episode mania. Methods: The design was a single-blind, randomised controlled trial on a cohort of 61 participants following first episode mania. Participants received either lithium or quetiapine monotherapy as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive cognitive assessment battery conducted at baseline, month 3 and month 12 follow-up time-points. Results: There was a significant interaction between group and time in phonemic fluency at the 3-month and 12-month endpoints, reflecting greater improvements in performance in lithium-treated participants relative to quetiapine-treated participants. After controlling for multiple comparisons, there were no other significant interactions between group and time for other measures of cognition. Conclusion: Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder. Given that cognition is a major symptomatic domain of bipolar disorder and has substantive effects on general functioning, the ability to influence the trajectory of cognitive change is of considerable clinical importance.

KW - Mania

KW - Bipolar disorder

KW - Cognition

KW - Lithium

KW - Quetiapine

KW - Early intervention

UR - http://ac.els-cdn.com/S0924933815006410/1-s2.0-S0924933815006410-main.pdf?_tid=c1e64ef2-f79b-11e5-8d6f-00000aab0f26&acdnat=1459468585_9cc5aa55c9802d1d

U2 - 10.1016/j.eurpsy.2015.09.460

DO - 10.1016/j.eurpsy.2015.09.460

M3 - Article

VL - 31

SP - 20

EP - 28

JO - European Psychiatry

JF - European Psychiatry

SN - 0924-9338

ER -